moncefem/clinical-trials-ai-2000-2025 huggingface dataset:
A Multiomics-based Study of the Immune Function of Colorectal Cancer Lymph Nodes
Trial ID: NCT06319404
Status: UNKNOWN
Study type: OBSERVATIONAL
Start date: 2024-04-01
Completion date: 2026-04-01
Sponsor: Shanxi Province Cancer Hospital
Collaborators: The Second Affiliated Hospital of Harbin Medical University; Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions: Colorectal Cancer; Lymph Node
Interventions: [None]
Enrollment: 500
Age range: 18 Years - 75 Years
Sex: ALL

Summary:
Lymph nodes are very important immune organs in the human body and play an important role in the physiological and pathological activities of the body, especially in anti-tumor immunity. The role of regional draining lymph nodes in the development of colorectal cancer is still unknown. In this study, the role of lymph nodes in the development of colorectal cancer was investigated through multicenter and multi-omics data.

Eligibility criteria:
Inclusion Criteria:

* Stage I-III colorectal cancer patients undergoing radical surgery
* Complete imaging, pathology and genetics multi-omics data available
* 18-75 years old

Exclusion Criteria:

* Patients with preoperative neoadjuvant therapy
* Patients with incomplete clinical information
* Patients with other malignant tumors
* Patients with acute infections or untreated chronic infections

Outcomes:
To investigate the difference of immune pathway activation in tumor-draining lymph node based on genomics; To investigate the relationship between the type and number of immune cells in tumor draining lymph nodes and the activation of immune pathways is based on pathomics; The immune function of tumor draining lymph nodes of colorectal cancer patients was previously identified based on radiomics
Using Artificial Intelligence-assisted Optical Polyp Diagnosis for Diminutive Colorectal Polyps
Trial ID: NCT06059378
Status: RECRUITING
Study type: INTERVENTIONAL
Phase: NA
Start date: 2023-09-01
Completion date: 2025-06-30
Sponsor: Daniel Von Renteln
Conditions: Artificial Intelligence
Interventions: Artificial intelligence-assisted classification (CADx)
Locations: Centre Hospitalier de l'Université de Montréal
Countries: Canada
Enrollment: 204
Age range: 45 Years - 80 Years
Sex: ALL

Summary:
This is a prospective study that is the first to implement resect and discard and diagnose and leave strategies in real-time practice using stringent documentation and adjudication by 2 expert endoscopists as the gold standard.

The primary aim of this study is to show the accuracy of intracolonoscopy AI-assisted optical diagnosis (CADx; autonomous or with human input) when the AI-assisted optical diagnosis made by the expert endoscopists is used as the reference standard. The specific aims are:

1. To evaluate the accuracy of intracolonoscopy AI-assisted optical polyp diagnosis (autonomous or with human input) by comparing it to the obtained optical histology diagnoses provided by two independent expert endoscopists as the reference standard.
2. To evaluate the agreement between the intracolonoscopy AI-assisted optical polyp diagnosis (autonomous or with human input) and the AI-assisted optical diagnosis performed by two independent expert endoscopists.
3. To determine whether AI-assisted optical polyp diagnosis for diminutive (1-5 mm) polyps can be implemented in routine clinical practice by demonstrating that at least 70% of the approached patients are interested in undergoing AI-assisted optical diagnosis (autonomous or with human input).
4. To evaluate the cost savings resulting from replacing pathology with AI-assisted optical diagnosis.

Eligibility criteria:
Inclusion Criteria:

* Age 45-80 years
* Undergoing an outpatient colonoscopy at the Centre Hospitalier de l'Université de Montréal (CHUM)
* Signed informed consent form

Exclusion Criteria:

* Inflammatory Bowel Disease;
* Active colitis;
* Hereditary CRC syndrome;
* Coagulopathy;
* American Society of Anesthesiologists (ASA) status \>3

Outcomes:
Accuracy of the intracolonoscopy AI-assisted optical diagnosis
Clinical Performance of AI-based TruRoot Designed Clear Aligner (A Randomized Clinical Trial)
Trial ID: NCT06968325
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Phase: NA
Start date: 2025-02-25
Completion date: 2026-12-01
Sponsor: University of Baghdad
Conditions: Root Resorption; Pain Perception; Treatment Duration
Interventions: AI-based TruRoot group:; Conventional clear aligner group
Locations: College of Dentistry, University of dentistry
Countries: Iraq
Enrollment: 40
Age range: 18 Years - 30 Years
Sex: ALL

Summary:
The goal of this clinical trial is to evaluate the clinical performance and validity of applying AI-based TruRoot-designed clear aligners in adult orthodontic patients. The main questions it aims to answer are:

Do TruRoot-designed aligners achieve more accurate root positioning compared to conventional aligners?

Is there a significant difference in clinical parameters such as root resorption, pain levels, treatment duration, and occlusal outcomes between the two groups?

Is the TruRoot AI-based design a valid and clinically applicable method for planning clear aligner treatment?

Researchers will compare:

An AI-based TruRoot group, where aligners are planned using CBCT and intraoral scan superimposition to estimate true root position

A Conventional group, where aligners are designed using intraoral scans only, with expert evaluation to ensure roots remain within the alveolar bone

Participants will:

Receive clear aligner treatment based on either the TruRoot AI system or conventional planning by experts

Undergo CBCT and intraoral scans at baseline and post-treatment

Be assessed for root position accuracy, validity of AI-generated treatment plans, occlusal outcomes via the ABO Objective Grading System, root resorption, self-reported pain, and treatment duration

Attend regular follow-ups throughout the treatment period

Eligibility criteria:
Inclusion Criteria:

1. All participants should have good general health with healthy periodontium.
2. Adult patient with an age range 18-30 with fully erupted all permanent dentitions excluding third molars.
3. Skeletal and dental Cl I malocclusion with moderate crowding (little irregularity index 4-6 mm).
4. The treatment plan should be non-extraction treatment.
5. No history of trauma or root resorption

Exclusion Criteria:

1. Patients with diseases or syndromes affecting maxillofacial regions,
2. Subject with poor oral hygiene.
3. Defective and missing teeth.
4. Presence of any deep bite or open bite problems,
5. History of trauma, root resorptions and dilacerated roots.
6. Medical conditions affecting tooth movement or bone metabolism.
7. previous extraction or history of previous orthodontic treatment.

Outcomes:
Root position and movement; Assessment of Root Position Relative to Alveolar Bone
A New Method to Differentiate Benign and Malignant Pulmonary Nodules by Mass Spectrometry Combined With Artificial Intelligence.
Trial ID: NCT06056999
Status: RECRUITING
Study type: OBSERVATIONAL
Start date: 2023-09-29
Completion date: 2025-07
Sponsor: China-Japan Friendship Hospital
Conditions: Pulmonary Nodules
Locations: China-Japan Friendship Hospital
Countries: China
Enrollment: 150
Age range: 18 Years - None
Sex: ALL

Summary:
The goal of this observational clinical trial is to establish a new method for differentiating benign and malignant pulmonary nodules by peripheral blood detection in patients with pulmonary nodules (\<3cm). The main questions it aims to answer is: How to combine blood metabolomic mass spectrometry detection and artificial intelligence image analysis to establish a new model for differentiating benign and malignant pulmonary nodules. Participants will be asked provide 4 mL peripheral blood for the test.

Eligibility criteria:
Inclusion Criteria:

* Age ≥18 years;
* CT imaging shows the presence of pulmonary nodule \<3cm which is scheduled for puncture biopsy or surgery (i.e., the target lesion), the presence of ≥2 target lesions of the same type (categorized by density) are allowed;
* Subjects are in good condition with Eastern Cooperative Oncology Group (ECOG) scale of 0-2;
* Subjects with fair vital organ function, defined as: white blood cells ≥3.0×10\^9/L, platelets ≥75×10\^9/L, hemoglobin ≥90g/L, alanine aminotransferase and aspartate aminotransferase ≤2.5 times the upper limit of normal values, and serum creatinine \<178μmol/L;
* Subjects must have the ability to understand and sign the informed consent in writing voluntarily.

Exclusion Criteria:

* Imaging examination have suggested the possibility of metastasis at other sites;
* ≥2 target lesions with different type categorized by density;
* History of malignant disease;
* Severe vascular lesions within the last 3 months, or known significant active infection, during acute/chronic tuberculosis infection, or severe cardiovascular and cerebrovascular diseases, dysfunction of liver and renal, or significant endocrine and metabolic disorders, or other serious concomitant diseases that are not controlled;
* The specialist/surgeon assessed that puncture or surgery is not available, with contraindication such as coagulation disorders, cardiorespiratory insufficiency, etc.;
* History of uncontrolled epilepsy, central nervous system disease, or psychiatric disorders, that may affect the signing of informed consent;
* Pregnant or breastfeeding women;
* Other conditions deemed by the investigator to be unsuitable for enrollment.

Outcomes:
Establish an model for differentiating lung nodules.
A Stepped Wedged, Cluster Randomized Clinical Trial to Evaluate the Efficacy of a Clinical Decision Support Tool in the Treatment of Uncontrolled Hypertension
Trial ID: NCT07218198
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Phase: NA
Start date: 2026-07-01
Completion date: 2027-12-01
Sponsor: The Cleveland Clinic
Conditions: Hypertension; Hypertension (HTN); Blood Pressure, High; Blood Pressure Control
Interventions: Standard medical treatment; Clinical Decision Support Tool
Locations: Cleveland Clinic
Countries: United States
Enrollment: 168
Age range: 18 Years - None
Sex: ALL

Summary:
The goal of this clinical trial is to study whether having a clinical decision support (CDS) tool available to clinician use will more effectively lower BP 4 weeks after an outpatient visit compared with usual care. The main objective is to assess the impact of the CDS tool, that is embedded with the electronic medical record (EMR), that is available during outpatient clinical encounters, on blood pressure (BP) changes among participants with uncontrolled hypertension.

Participants will:

Visit the clinic 4 weeks, after their initial clinician visit, for a BP check.

Eligibility criteria:
Inclusion Criteria:

1. Men and women 18 years of age or older
2. Electronic Health Record (EHR) of hypertension AND prescribed at least one BP lowering medication
3. Office systolic BP of 130 mmHg or higher
4. Willing and able to comply with the study instructions AND attend a scheduled study visit

Exclusion Criteria:

1. Women who are pregnant, plan to become pregnant, or are breast-feeding
2. Know heart failure with reduced ejection fraction and a left ventricular ejection fraction of less than 40%
3. End-stage kidney disease currently undergoing renal replacement therapy, or an eGFR \< 15ml/min/1.73m2
4. In the opinion of the investigator, any other condition that will preclude participation in the study

Outcomes:
Change in systolic automated office blood pressure (AOBP)
Financial Coaching and Lifestyle Intervention for Diabetes Prevention in Low-income Families
Trial ID: NCT05944549
Status: COMPLETED
Study type: INTERVENTIONAL
Phase: NA
Start date: 2023-05-12
Completion date: 2025-02-15
Sponsor: The University of Texas Health Science Center, Houston
Collaborators: Bank of America Foundation
Conditions: Weight Loss
Interventions: Financial coaching using TrustPlus; Brighter Bites; Noom
Locations: The University of Texas Health Science Center at Houston
Countries: United States
Enrollment: 58
Age range: 18 Years - None
Sex: ALL

Summary:
The purpose of this study is to compare the effect on weight and metabolic outcomes of an enhanced intervention, comprised of evidence-based financial coaching plus a lifestyle intervention vs. the lifestyle intervention alone

Eligibility criteria:
Inclusion Criteria:

* English speaking parents
* BMI\>25.0 at baseline
* must have a child participant in the Brighter Bites program at study enrollment
* own a smartphone (Android 6 and iPhone 12.4 or later)
* must able to participate in study activities

Exclusion Criteria:

* medications known to affect appetite or body composition (e.g., corticosteroids, antidepressants, beta blockers, sulfonylureas, insulin)
* currently diagnosed with conditions known to affect body composition or fat distribution (e.g., Cushing's syndrome, hypothyroidism)
* diagnosis of an eating disorder
* currently pregnant.

Outcomes:
Percent weight loss; Percent weight loss
ARON-2 Study-Multicentric International Retrospective Study
Trial ID: NCT05290038
Status: RECRUITING
Study type: OBSERVATIONAL
Start date: 2022-02-17
Completion date: 2027-09-30
Sponsor: Matteo Santoni
Conditions: Urothelial Carcinoma
Locations: Ospedale di Macerata, UOC Oncologia
Countries: Italy
Enrollment: 367
Age range: 18 Years - None
Sex: ALL

Summary:
The ARON-2 study retrospectively analyze patients treated with pembrolizumab as first-line therapy in patients platinum-unfit or as second-line therapy in patients progressed after previous platinum-based chemotherapy. The amendment has been designed to also analyze patients treated with enfortumab vedotin progressed to previous platinum-based chemotherapy and anti-PD-1/PD-L1 inhibitor.

Eligibility criteria:
Inclusion Criteria:

* Patients aged \>18y
* Histologically confirmed diagnosis of UC of upper and/or lower urinary tract
* Histologically or radiologically confirmed metastatic disease
* Patients treated with at least one of the following:
* Treatment with pembrolizumab in patients progressed after previous platinum-based chemotherapy or as first-line therapy in patients platinum-unfit, and at least 1 cycle of pembrolizumab within the period from 1 January 2018 to 30 November 2021
* Treatment with enfortumab vedotin in patients progressed to previous platinum-based chemotherapy and anti-PD-1/PD-L1 inhibitor and at least 1 cycle of enfortumab vedotin within the period from June 1st 2022 to July 31st 2023

Exclusion Criteria:

* Patients without histologically confirmed diagnosis of UC
* Patients without histologically or radiologically confirmed metastatic disease

Outcomes:
Overall Survival (OS) of patients with metastatic Urothelial Cancer (UC) treated with pembrolizumab or enfortumab vedotin; Progression-Free Survival (PFS) of patients with metastatic Urothelial Cancer (UC) treated with pembrolizumab or enfortumab vedotin; Overall Response Rate (ORR) of patients with metastatic Urothelial Cancer (UC) treated with pembrolizumab or enfortumab vedotin
A Multicenter Prospective Observational Study of Computer-aided Risk Perception and Prognosis Prediction in the Whole Process of Laparoscopic Hepatobiliary and Pancreatic Surgery
Trial ID: NCT06647264
Status: ENROLLING_BY_INVITATION
Study type: OBSERVATIONAL
Start date: 2024-09-01
Completion date: 2027-01-01
Sponsor: Nanfang Hospital, Southern Medical University
Collaborators: The Affiliated Hospital Of Southwest Medical University; Affiliated Hospital of Guangdong Medical University; Huzhou Central Hospital; Guangdong Provincial Hospital of Traditional Chinese Medicine; Jiangmen Central Hospital; Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences; Chinese University of Hong Kong; Shenzhen Second People's Hospital; Shenzhen Third People&#39;s Hospital
Conditions: Hepatocellular Carcinomas; Cholecystectomy, Laparoscopic; Hepatectomy; Pancreatoduodenectomy
Locations: Department of hepatobiliary surgery, Nanfang Hospital, Southern Medical University
Countries: China
Enrollment: 1500
Age range: 18 Years - 80 Years
Sex: ALL

Summary:
Artificial intelligence technology is used to realize high-quality 3D scene reconstruction, whole process segmentation, scene activity understanding for common surgery guidance in hepatobiliary surgery, as well as intelligent identification, perception, early warning of key events in the whole process of endoscopic surgery (such as bleeding, blocking, tumor location, anastomosis, etc.), and decision-making assistance

Eligibility criteria:
Inclusion Criteria:

* Voluntarily sign informed consent Patients who underwent hepatectomy and cholecystectomy and were followed up in the research center hospitals from July 2024 to December 2028 Complete case, imaging and operation video data

Exclusion Criteria:

* Patients who had other diseases before surgery, which may affect the results of the study Patients who developed postoperative complications but could not confirm their relevance to surgery According to the judgment of the researcher, it is not suitable to participate in this study

Outcomes:
Main effectiveness indicators; Main effectiveness indicators
Evaluation of a Novel Auto Segmentation Algorithm for Normal Structure Delineation in Radiation Treatment Planning
Trial ID: NCT06200116
Status: RECRUITING
Study type: OBSERVATIONAL
Start date: 2024-12-02
Completion date: 2026-11-30
Sponsor: Mayo Clinic
Conditions: Malignant Solid Neoplasm; Hematopoietic and Lymphatic System Neoplasm
Interventions: Non-Interventional Study
Locations: Mayo Clinic in Arizona; Mayo Clinic in Florida; Mayo Clinic Health System in Albert Lea; Mayo Clinic Health Systems-Mankato; Mayo Clinic in Rochester; Mayo Clinic Health System-Eau Claire Clinic; Mayo Clinic Health System-Franciscan Healthcare
Countries: United States; United States; United States; United States; United States; United States; United States
Enrollment: 200
Age range: None - None
Sex: ALL

Summary:
This study measures the utility of a novel artificial intelligence (AI) algorithm for performing auto-segmentation of computed tomography (CT) scans for radiation therapy planning.

Eligibility criteria:
Inclusion Criteria:

* Employment at Mayo Clinic Arizona, Florida, or Rochester (which includes Regional Practice sites located at Mayo Clinic Health System locations) as train clinical staff that participate in normal tissue segmentation

Exclusion Criteria:

* Inability to complete study surveys

Outcomes:
Proportion of success
Research on Intelligent Assist System of Colonoscope Operating Handle
Trial ID: NCT04765163
Status: UNKNOWN
Study type: OBSERVATIONAL
Start date: 2019-05-11
Completion date: 2021-11-30
Sponsor: Beijing Tsinghua Chang Gung Hospital
Conditions: Colonic Disease
Interventions: Intelligent Operating Handle
Locations: Wang Ruigang
Countries: China
Enrollment: 2
Age range: 18 Years - 65 Years
Sex: ALL

Summary:
Artificial intelligence is deeply integrated with medical diagnosis, and intelligent colonoscopy technology has broad room for development. At present, the assist device of colonoscopy is insufficiently studied. It is the part that needs to be further explored in the development of artificial intelligence colon diagnosis and treatment technology. The study will be conducted at the Digestive Endoscopy Center and it is expected that 380 subjects will participate voluntarily. Subjects met: 1) routine colonoscopy; 2) willing to provide relevant information required by the experiment; 3) signed informed consent for the study. This topic focuses on the colonoscope assist device, through the combination of power assisting device, dynamic analysis, and migration expert skills, to achieve a combination of intelligent power and precise treatment, and establish a prototype of the patient-colonoscopy-assisted assist system-doctor's four-in-one diagnosis and treatment system.

Eligibility criteria:
Inclusion Criteria:

1. routine colonoscopy;
2. Willing to provide relevant information required by this experiment;
3. Sign the informed consent form for this study.

Exclusion Criteria:

1. can not tolerate colonoscopy;
2. Information about the requirements of this study cannot be provided;
3. Questionnaires cannot be conducted.

Outcomes:
Colonoscope operating handle model
Accuracy of Artificial Intelligence Technology in Detecting Number of Root Canal of Human Mandibular Second Molar: Diagnostic Accuracy Experimental Study
Trial ID: NCT07319221
Status: COMPLETED
Study type: INTERVENTIONAL
Phase: NA
Start date: 2024-11-29
Completion date: 2025-12-20
Sponsor: Future University in Egypt
Conditions: Detecting Number of Root Canal of Human Mandibular Second Molar
Interventions: AI; CBCT
Locations: Future University Dental Hospital
Countries: Egypt
Enrollment: 40
Age range: 18 Years - 40 Years
Sex: ALL

Summary:
to detect the Accuracy of Artificial Intelligence Technology in Detecting Number of Root Canal of Human Mandibular Second Molar: Diagnostic Accuracy Experimental Study.

Eligibility criteria:
Inclusion Criteria:

\-

A- Inclusion criteria:

1. Patients must be medically free from any systemic disease that can affect root canal treatment.
2. Age range of the patients should be 18-40 with permanent mandibular second molars indicated for root canal treatment.
3. No sex predilection.
4. Patients must have good oral hygiene.
5. restorable teeth.
6. Positive patient"s acceptance for participating in the study.
7. Patients able to sign informed consent.

B- Exclusion criteria:

1. Lower second molars which are non-restorable, having large perforations, external root resorption, vertical root fracture, internal root resorption, grade 2/3 mobility, previous successful/non-successful root canal treatment
2. Pregnant women after taking detailed history and pregnancy test must be in the first visit.
3. Psychologically disturbed patients.

   Teeth that have:

   • Periodontally affected with grade 2 or 3 mobility. 12

   • Not restorable teeth.

   • Abnormal anatomy and calcified canals.

   • Previous root canal treatment.

Outcomes:
Number of root canals detected
The DAnish VIdeo IntubaTION (DA-VITION) Study: a Prospective Observational Cohort Study
Trial ID: NCT05884645
Status: RECRUITING
Study type: OBSERVATIONAL
Start date: 2023-05-01
Completion date: 2026-03-31
Sponsor: Lise Aunsholt
Collaborators: Copenhagen Academy for Medical Education and Simulation
Conditions: Intubation Complication; Intubation; Difficult or Failed
Interventions: Video-directed endotracheal intubation
Locations: Rigshospitalet; Capital Region of Denmark
Countries: Denmark; Denmark
Enrollment: 10000
Age range: None - None
Sex: ALL

Summary:
This study aims to train an AI for video-directed endotracheal intubation (VITION) to recognise the anatomical structures of the upper airway during video-directed endotracheal intubations.

Eligibility criteria:
Patients are eligible if they adhere to all the following inclusion criteria:

● Undergoing video-directed oral or nasal endotracheal intubation.

Exclusion criteria

Patients are excluded if they adhere to one of the exclusion criteria:

* Upper airway malformations (e.g., laryngomalacia, vocal cord paralysis, and subglottic stenosis).
* Failed attempt by video laryngoscopy due to malfunctioning equipment.
* Missing or corrupted video recording.
* Informed consent is not obtained from the participants or participants' parents / legal guardians.

Outcomes:
Accuracy of the AI algorithm to recognise the anatomical landmarks in the upper airway.; Sensitivity of the AI algorithm to recognise the anatomical landmarks in the upper airway.; Specificity of the AI algorithm to recognise the anatomical landmarks in the upper airway.; AUC of the AI algorithm to recognise the anatomical landmarks in the upper airway.